Receipt of $420k Research & Development Tax Refund
Filed with ASX · · 2 pages · English
Story so far
Earlier from Dimerix
- Corporate Presentation
- Key Patent Allowed in Japan
- Dimerix Raises $2 million to Advance Clinical Program
- Recruitment of Part A of Phase 2 Trial of DMX-200 Completed
- Appointment of Chief Executive Officer
Later from Dimerix
- Investor Update
- Research Validates Relevance of DMX Receptor-HIT Technology
- Positive Results from Phase 2a Trial of DMX-200
- DMX-200 tablet manufacture and human study timeline
- Notice of Annual General Meeting/Proxy Form
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix